United Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) EV/FCF
As of 5 November 2026, United Therapeutics Corporation (UTHR) trades at a EV/FCF of 24.2×. Over the past ten years it has ranged from −16.5× (April 2019) to 26.4× (November 2026); the current reading is higher than 98% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 18.3× | 50.61% |
| FY2024 | 12.2× | 8.21% |
| FY2023 | 11.2× | (30.47%) |
| FY2022 | 16.2× | (13.45%) |
| FY2021 | 18.7× | 118.72% |
| FY2020 | 8.5× | — |
| FY2019 | −10.9× | — |
| FY2018 | 6.5× | (59.45%) |
| FY2017 | 16.0× | 82.80% |
| FY2016 | 8.8× | (4.78%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 23.1× | 21.23% |
| Jun 2026 | 19.1× | (19.51%) |
| Mar 2026 | 23.7× | 29.21% |
| Dec 2025 | 18.3× | 28.08% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | 11.4× |
| TAK Takeda Pharmaceutical Co. compare | 11.7× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.5× |
| VTRS Viatris Inc. compare | 16.3× |
| ZTS Zoetis Inc. compare | 18.4× |
| UTHR United Therapeutics Corporation | 24.2× |
| ELAN Elanco Animal Health Incorporated compare | 42.7× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 46.2× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on UTHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement